COMPARATIVE-EVALUATION OF VARIOUS TREATME NT REGIMENS IN ACUTE NONLYMPHOBLASTIC LEUKEMIA

78 previously untreated patients with acute non-lymphoblastic leukemia (ANLL) were assigned to cytosar-anthracyclines therapeutic programs: 29 (group 1) received daunorubicin and AraC, 18 (group II) aclacinomyc in A and AraC, 12 (group III) the scheme 3+7 with 12 mg/m2 novantron i nstead of daunorubicin, 19 (group IV) the scheme 3+7 with 12 mg/m2 ida rubicin and cytosar. Groups I-III comprised both prognostically favora ble and unfaborable ANLL variants, group 4 patients had for the most p art unfavorable prognosis (MO-M3). A mean age of the patients was 41-4 2. Complete remissions were observed in 17 (58.6 %), 9 (50 %), 10 (83. 3 %), 11 (57.9 %) patients of groups I, II, III and IV, respectively. An initial course of the treatment produced complete remissions in 65 %, 33 %, 80 % and 90.9 % of them, respectively. A mean duration of cyt ostatic leukothrombocytopenia was the longest in groups III and IV (16 -22 days). Nonhematological toxicity occurred in the form of enteropat hy and hepatitis. During the remission induction and consolidation 76 % of the deaths were caused by infection and hemorrhagic diathesis. Th e median remission lasted 17.5, 13.5 and 5 months in groups I, II and III, respectively, and was not reached in group IV because of continui ng remission in 50 % of the patients by the end of the follow-up perio d (14 months). A 2-year survival rate was observed in 25 % (group I), 11 % (group I), 30 % (group III) and 40 % (group IV).